Cargando…

Dihydroergotamine (DHE) – Then and Now: A Narrative Review

OBJECTIVE: To provide a narrative review of clinical development programs for non‐oral, non‐injectable formulations of dihydroergotamine (DHE) for the treatment of migraine. BACKGROUND: Dihydroergotamine was one of the first “synthetic drugs” developed in the 20th century for treating migraine. It i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silberstein, Stephen D., Shrewsbury, Stephen B., Hoekman, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003832/ https://www.ncbi.nlm.nih.gov/pubmed/31737909 http://dx.doi.org/10.1111/head.13700

Ejemplares similares

Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations
por: Shafqat, Rafia, et al.
Publicado: (2020)

Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action
por: Cooper, Wade, et al.
Publicado: (2022)

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects
por: Albrecht, Detlef, et al.
Publicado: (2020)

Does DHE imaging shed insight into the inaccuracy of EKGs?
por: Nadour, Wadih, et al.
Publicado: (2009)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space
por: Martin, Vincent, et al.
Publicado: (2021)

Saclay : Applications des ions d'He en radiothérapie
Publicado: (1977)

STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(®)) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients
por: Smith, Timothy R., et al.
Publicado: (2021)

Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache
por: Robbins, Nathaniel M., et al.
Publicado: (2016)

Sumatriptan and dihydroergotamine in proximal and distal human isolated coronary arteries
por: Labruijere, S, et al.
Publicado: (2013)

Dihydroergotamine Complicating Reversible Cerebral Vasoconstriction Syndrome in Status Migrainosus
por: Mullaguri, Naresh, et al.
Publicado: (2018)

Disheveled Hair and Ear (Dhe), a Spontaneous Mouse Lmna Mutation Modeling Human Laminopathies
por: Odgren, Paul R., et al.
Publicado: (2010)

The decisive role of cardiovascular MRI delayed hyperenhancement (DHE) pattern for risk stratification for dilated cardiomyopathy
por: Venero, Jose V, et al.
Publicado: (2009)

Digital Health Europe (DHE) Twinning on severe asthma—kick-off meeting report
por: Bousquet, Jean, et al.
Publicado: (2021)

Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat
por: Tfelt-Hansen, Peer, et al.
Publicado: (2007)

Infection susceptibility and immune senescence with advancing age replicated in accelerated aging Lmna (Dhe) mice
por: Xin, Lijun, et al.
Publicado: (2015)

Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
por: Bérard, Anick, et al.
Publicado: (2021)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2023)

Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection
por: Stagnoli, Soledad, et al.
Publicado: (2023)

Celecoxib Oral Solution and the Benefits of Self-Microemulsifying Drug Delivery Systems (SMEDDS) Technology: A Narrative Review
por: Silberstein, Stephen, et al.
Publicado: (2023)

Neuropeptide release from slices of rat and guinea pig trigeminal ganglia: modulation by dihydroergotamine and sumatriptan
por: Tognetto, Michele, et al.
Publicado: (2000)

Mitotic Defects Lead to Pervasive Aneuploidy and Accompany Loss of RB1 Activity in Mouse Lmna(Dhe) Dermal Fibroblasts
por: Pratt, C. Herbert, et al.
Publicado: (2011)

A snapshot of lung cancer: where are we now?—a narrative review
por: Ibodeng, Gogo-ogute, et al.
Publicado: (2023)

Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor
por: Zheng, Ke-Xin, et al.
Publicado: (2023)

The Upper Nasal Space: Option for Systemic Drug Delivery, Mucosal Vaccines and “Nose-to-Brain”
por: Shrewsbury, Stephen B.
Publicado: (2023)

The Pharmacokinetics of Drugs Delivered to the Upper Nasal Space
por: Shrewsbury, Stephen B.
Publicado: (2023)

536 Effect of Diet Supplementation with Epa-Dhe on Pulmonary Function Tests and Metacholine Bronchial Challenge Test in Obese Mexican Children
por: Pineda-Bahena, Luisa Guadalupe, et al.
Publicado: (2012)

In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2020)

Multiorgan Development of Oxidative and Nitrosative Stress in LPS-Induced Endotoxemia in C57Bl/6 Mice: DHE-Based In Vivo Approach
por: Proniewski, Bartosz, et al.
Publicado: (2019)

Artificial intelligence in esophageal cancer diagnosis and treatment: where are we now?—a narrative review
por: Merchán Gómez, Beatriz, et al.
Publicado: (2023)

EHMTI-0125. Studying the permeability of the blood-brain barrier during migraine attacks using [11C]-dihydroergotamine
por: Schankin, C, et al.
Publicado: (2014)

Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors
por: González-Hernández, Abimael, et al.
Publicado: (2018)

The role of α(1)- and α(2)-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats
por: Rivera-Mancilla, Eduardo, et al.
Publicado: (2017)

Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine
por: Noveck, Robert J, et al.
Publicado: (2013)

Brachial Artery Vasospasm From Sequential Use of Intravenous Promethazine and Dihydroergotamine for Treatment of Status Migrainosus: A Case Report
por: Johns, Christopher, et al.
Publicado: (2023)

Quality of Life, Psychological Wellbeing, and Sexuality in Women with Urinary Incontinence—Where Are We Now: A Narrative Review
por: Frigerio, Matteo, et al.
Publicado: (2022)

Petasites for Migraine Prevention: New Data on Mode of Action, Pharmacology and Safety. A Narrative Review
por: Borlak, Jürgen, et al.
Publicado: (2022)

Evaluation of a Monthly Coverage Maximum (Drug-Specific Quantity Limit) on the 5-HT1 Agonists (Triptans) and Dihydroergotamine Nasal Spray
por: Hoffman, Lauren, et al.
Publicado: (2003)

Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors
por: Kori, S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kkuv4u24vehkmh7uuth5sbs6t7